10x Genomics (TXG): What Does the Company Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Summary
10x Genomics (TXG) is a life-sciences technology company that provides single-cell and spatial genomics analysis tools. Its earnings and stock price are driven by instrument and consumables demand, research budgets, and the adoption of new products, and the stock is notable for its leadership in precision biology, drawing strong interest for its outlook and related stocks.
What is 10x Genomics?
10x Genomics (TXG) is a life-sciences technology company that provides single-cell and spatial genomics analysis tools. Headquartered in California, USA, the company supplies instruments, consumables, and software for single-cell and spatial biology research, used by research institutions and pharmaceutical companies in precision biology studies.
The company's core business is supplying instruments, consumables, and analysis software for single-cell and spatial biology analysis. With strengths in recurring consumables revenue following instrument sales, an extensive patent portfolio, and leading-edge technology, the company is a life-sciences tools business exposed to precision biology research demand from research institutions and pharmaceutical companies.
💰 How Does 10x Genomics Make Money?
| Business Segment | Revenue Share | Description | ||||||
|---|---|---|---|---|---|---|---|---|
| Consumables | Core | Single-cell and spatial analysis consumables | ||||||
| Instruments | Key Growth Driver | Analysis instrument sales | ||||||
| Software & Services | Diversification Driver | Analysis software and services |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| ILMN | Illumina Inc | $205.10 | +0.0% | $31.0B | 38.2 | 11.7 | 32.38% | - |
 PACB | Pacific Biosciences of California Inc | $1.40 | -5.4% | $434.8M | - | 183.7 | -273.55% | - |
 TWST | Twist Bioscience Corp | $91.55 | +0.2% | $5.7B | - | 12.5 | -18.16% | - |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| A | Agilent Technologies Inc | $138.37 | -0.3% | $39.1B | 27.8 | 5.5 | 21.33% | 0.74% |
| TMO | Thermo Fisher Scientific Inc | $574.30 | -0.4% | $213.4B | 30.9 | 4.1 | 13.53% | 0.32% |
✅ Investor Checklist for 10x Genomics
Key points to review when investing in 10x Genomics. Research and biotech budgets, the installed instrument base, recurring consumables revenue, the adoption of new products, and patent disputes act as key short- and medium-term variables.
| Checklist | What to Confirm | Current Status |
|---|---|---|
| Research Demand | Single-cell and spatial research demand | Structural Growth |
| Consumables | Instrument installations and consumables revenue | Recurring Revenue |
| New Products | Adoption of new products such as spatial biology | Growth Driver |
| Budgets | Research and biotech budgets | Cyclical Sensitivity |
A core risk is demand contraction when research and biotech budgets slow. Patent disputes with competitors, intensifying competition in the genomics tools field, and the pace of profitability during the growth-investment phase can also act as factors of variability in earnings and the stock price.
10x Genomics is a life-sciences tools company with leading technology in the single-cell and spatial analysis field and recurring consumables revenue, with strengths in an extensive patent portfolio and new-product growth. However, given its sensitivity to research budgets and patent/competition dynamics, staggered buying and a long-term perspective are recommended.
이 글은 2026년 6월 7일 기준 정보입니다.